Affiliation:
1. Spero Therapeutics Inc., Cambridge, Massachusetts, USA
Abstract
Carbapenem-resistant
Acinetobacter baumannii
and
Enterobacterales
are identified as urgent threats, and multidrug-resistant (MDR)
Pseudomonas aeruginosa
and extended-spectrum beta-lactamase (ESBL)-producing pathogens are identified as serious threats by the Centers for Disease Control and Prevention (CDC). SPR206 is a novel polymyxin derivative with potent
in vitro
and
in vivo
activity against
A. baumannii
,
P. aeruginosa
, and multiple clinically important species of
Enterobacterales
, including multidrug- and extensively drug-resistant strains.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献